Details of the Drug Combination

General Information of Drug Combination (ID: DCTQSTB)

Drug Combination Name
Fludeoxyglucose F 18 Alovudine
Indication
Disease Entry Status REF
Melanoma Phase 1 [1]
Component Drugs Fludeoxyglucose F 18   DMAIL4L Alovudine   DMJPV5X
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Fludeoxyglucose F 18
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [2]
Indication(s) of Alovudine
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [3]
Alovudine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02891616) 18F-FLT PET Imaging in Patients With Advanced Melanoma
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 ClinicalTrials.gov (NCT02232581) Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure. U.S. National Institutes of Health.
4 Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.